{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:46:50Z","timestamp":1791704810229,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2025QC991"],"award-info":[{"award-number":["ZR2025QC991"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tranon.2026.103053","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:26:07Z","timestamp":1790576767000},"page":"103053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integrative analysis of m6A-related genetic variants and single-cell RNA sequencing identifies HLA-DQA1\/HLA-DQB1-associated immune signatures in CAR-T-treated diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"73","author":[{"given":"Ji-Mo","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.103053_bib0001","article-title":"Lymphoma dissemination is a pathological hallmark for malignant progression of B-cell lymphoma","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.tranon.2026.103053_bib0002","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.4103\/jfmpc.jfmpc_2432_21","article-title":"Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment","volume":"11","author":"Mamgain","year":"2022","journal-title":"J. Family Med. Prim. Care"},{"key":"10.1016\/j.tranon.2026.103053_bib0003","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/OTT.S326632","article-title":"Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options","volume":"15","author":"Vodicka","year":"2022","journal-title":"Onco Targets Ther."},{"issue":"3","key":"10.1016\/j.tranon.2026.103053_bib0004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PPO.0000000000000450","article-title":"Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma","volume":"26","author":"Roschewski","year":"2020","journal-title":"Cancer J."},{"issue":"4","key":"10.1016\/j.tranon.2026.103053_bib0005","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tranon.2026.103053_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1124360","article-title":"Molecular classification and therapeutics in diffuse large B-cell lymphoma","volume":"10","author":"Shimkus","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"10","key":"10.1016\/j.tranon.2026.103053_bib0007","doi-asserted-by":"crossref","first-page":"561","DOI":"10.5732\/cjc.012.10198","article-title":"Germinal-center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases","volume":"32","author":"Chen","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.tranon.2026.103053_bib0008","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.14694\/EdBook_AM.2015.35.e449","article-title":"ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection?","author":"Nowakowski","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.tranon.2026.103053_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211072839","article-title":"MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy","volume":"13","author":"Chen","year":"2022","journal-title":"Ther. Adv. Hematol."},{"issue":"22","key":"10.1016\/j.tranon.2026.103053_bib0010","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.12998\/wjcc.v10.i22.7994","article-title":"Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: a case report","volume":"10","author":"Huang","year":"2022","journal-title":"World J. Clin. Cases"},{"issue":"10","key":"10.1016\/j.tranon.2026.103053_bib0011","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.3390\/cancers12102913","article-title":"Oncogenic mutations of MYD88 and CD79B in diffuse large b-cell lymphoma and implications for clinical practice","volume":"12","author":"Visco","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-021-01155-2","article-title":"Molecular subgroups of diffuse large B cell lymphoma: biology and implications for clinical practice","volume":"24","author":"Weber","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"15","key":"10.1016\/j.tranon.2026.103053_bib0013","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.tranon.2026.103053_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.tranon.2026.103053_bib0015","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tranon.2026.103053_bib0016","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1111\/bjh.19778","article-title":"EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type","volume":"205","author":"Sherif","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.103053_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/2040620721989579","article-title":"Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma","volume":"12","author":"Candelaria","year":"2021","journal-title":"Ther. Adv. Hematol."},{"issue":"2","key":"10.1016\/j.tranon.2026.103053_bib0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care","volume":"17","author":"Vassilakopoulos","year":"2012","journal-title":"Oncologist"},{"issue":"9880","key":"10.1016\/j.tranon.2026.103053_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.tranon.2026.103053_bib0020","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tranon.2026.103053_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101002","article-title":"Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: other modes of transportation","volume":"57","author":"Sermer","year":"2023","journal-title":"Blood Rev."},{"key":"10.1016\/j.tranon.2026.103053_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.837457","article-title":"CD19-targeted immunotherapies for diffuse large B-cell lymphoma","volume":"13","author":"Gambella","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.103053_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.tranon.2026.103053_bib0024","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tranon.2026.103053_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1305657","article-title":"Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma","volume":"11","author":"Negishi","year":"2024","journal-title":"Front. Pediatr."},{"issue":"3","key":"10.1016\/j.tranon.2026.103053_bib0026","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s12276-023-00944-y","article-title":"The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications","volume":"55","author":"Liu","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.103053_bib0027","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020105977","article-title":"M(6) A RNA methylation: from mechanisms to therapeutic potential","volume":"40","author":"He","year":"2021","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.tranon.2026.103053_bib0028","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/biom14081042","article-title":"The role of m6A methylation in tumor immunity and immune-associated disorder","volume":"14","author":"Mu","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-023-00386-2","article-title":"Emerging roles of m6A RNA modification in cancer therapeutic resistance","volume":"12","author":"Liu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-022-00281-2","article-title":"The importance of N6-methyladenosine modification in tumor immunity and immunotherapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.103053_bib0031","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-7717-8_6","article-title":"An overview of genome-wide association studies","volume":"1754","author":"Chang","year":"2018","journal-title":"Methods Mol. Biol."},{"issue":"7944","key":"10.1016\/j.tranon.2026.103053_bib0032","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"issue":"D1","key":"10.1016\/j.tranon.2026.103053_bib0033","doi-asserted-by":"crossref","first-page":"D1388","DOI":"10.1093\/nar\/gkac750","article-title":"RMDisease V2.0: an updated database of genetic variants that affect RNA modifications with disease and trait implication","volume":"51","author":"Song","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"1620","key":"10.1016\/j.tranon.2026.103053_bib0034","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2012.0362","article-title":"Expression quantitative trait loci: present and future","volume":"368","author":"Nica","year":"2013","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.tranon.2026.103053_bib0035","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gkr917","article-title":"HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants","volume":"40","author":"Ward","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tranon.2026.103053_bib0036","doi-asserted-by":"crossref","first-page":"D258","DOI":"10.1093\/nar\/gkh036","article-title":"The gene ontology (GO) database and informatics resource","volume":"32","author":"Harris","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.tranon.2026.103053_bib0037","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.103053_bib0038","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-3578-9_5","article-title":"The gene expression omnibus database","volume":"1418","author":"Clough","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"10.1016\/j.tranon.2026.103053_bib0039","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.tranon.2026.103053_bib0040","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.12659\/MSM.907864","article-title":"Identification of HLA-DQA1 as a susceptibility gene for spinal tuberculosis by exome sequencing","volume":"24","author":"Shen","year":"2018","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0041","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2347441","article-title":"Principles of risk assessment in colon cancer: immunity is key","volume":"13","author":"Hijazi","year":"2024","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0042","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/cancers12010185","article-title":"Molecular complexity of diffuse large B-cell lymphoma: can it be a roadmap for precision medicine?","volume":"12","author":"Coccaro","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.tranon.2026.103053_bib0043","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1878-0261.13326","article-title":"RNA m(6) A methylation in cancer","volume":"17","author":"Wang","year":"2023","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr. Probl. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0045","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2023.066","article-title":"CAR-T cell therapy in large B cell lymphoma","volume":"15","author":"Testa","year":"2023","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"20","key":"10.1016\/j.tranon.2026.103053_bib0046","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1158\/1078-0432.CCR-23-0178","article-title":"Single-cell RNA analysis reveals cell-intrinsic functions of CAR T cells correlating with response in a phase II study of lymphoma patients","volume":"29","author":"Saren","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.tranon.2026.103053_bib0047","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00262-024-03756-9","article-title":"Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma","volume":"73","author":"Wu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0048","article-title":"Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells","volume":"12","author":"Li","year":"2022","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.tranon.2026.103053_bib0049","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.tranon.2026.103053_bib0050","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"issue":"33","key":"10.1016\/j.tranon.2026.103053_bib0051","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303502","article-title":"A lightweight framework for chromatin loop detection at the single-cell level","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci."},{"issue":"23","key":"10.1016\/j.tranon.2026.103053_bib0052","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202416432","article-title":"Unveiling multi-scale architectural features in single-cell Hi-C data using scCAFE","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332600389X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332600389X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:28:39Z","timestamp":1791703719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332600389X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":52,"alternative-id":["S193652332600389X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103053","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative analysis of m6A-related genetic variants and single-cell RNA sequencing identifies HLA-DQA1\/HLA-DQB1-associated immune signatures in CAR-T-treated diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103053"}}